However, all genes associated with DNA repair or that can trigger synthetic lethality are not known, and identifying mutations in DNA damage response proteins and repair pathways may become one of the main criteria for selecting PARP1 inhibitors for cancer treatment. The gene discussed is PARP1; the disease is cancer.